GenePlanet has announced it has closed a €10 million equity deal in exchange for a qualified minority stake with Zurich-based JF Investments.
The funds will be used for product development and international expansion. One of the key new products will be Health Intelligence – a platform which will be integrating biological data (genetic predispositions and current status of blood biomarkers) with information from smart devices and wearables to provide recommendations and action plans based on objective needs. The result will be a digital health engagement platform that improves health, vitality and well-being of people through a personalised prevention programme.
‘The investment will help us to develop our successful product portfolio beyond genetics. The most important asset people have is their health. We believe that our Health Intelligence platform will bring better results than the currently available solutions and will help our customers to live a healthier lifestyle’, GenePlanet’s CEO and Founder, Marko Bitenc.
GenePlanet will expand its business to Asia due to its market size and potential. The company will also consider opening an office in London to strengthen its presence in the UK and Western Europe.
GenePlanet was established in 2008 by its founder Marko Bitenc and is co-owned by an investment vehicle controlled by Austrian equity investor Gabriel Dielacher, a former Managing Director with Creditanstalt Investment Bank (CAIB). GenePlanet is specialised in genetic testing and related advanced molecular techniques. The company offers personalised DNA analyses in more than 30 countries.
